Form 4: Sutro Biopharma Executive Venkatesh Srinivasan Reports Stock Transactions
SEC Form 4 Filing
Venkatesh Srinivasan, Chief Technical Operations Officer of Sutro Biopharma, reports the vesting and subsequent tax withholding of shares related to restricted stock units.
Summary
- On April 11, 2024, Venkatesh Srinivasan, Chief Technical Operations Officer of Sutro Biopharma, engaged in transactions involving the company's common stock.
- 21,250 shares were acquired through the vesting of Restricted Stock Units (RSUs).
- 7,582 shares were withheld by the issuer to cover income tax obligations related to the RSU settlement at a price of $4.5 per share.
- Following these transactions, Srinivasan directly owns 30,122 shares of Sutro Biopharma common stock and 42,500 RSUs.
- The RSUs vest in equal annual installments, starting on April 11, 2023.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions, with no inherent positive or negative sentiment.
Industry Context
Form 4 filings are standard practice for reporting insider transactions and provide transparency into the trading activities of company executives.
Key Dates
| Date | Description |
|---|---|
| 04/11/2023 | Initial vesting date for the RSUs, with 1/4th of the total shares vesting annually. |
| 04/11/2024 | Date of the reported transactions: RSU vesting and tax withholding. |
| 04/12/2024 | Date of the form filing. |
| 04/11/2026 | Expiration date of the Restricted Stock Units. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.